| 1.7 -0.06 (-3.41%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.2 | 1-year : | 2.45 |
| Resists | First : | 1.88 | Second : | 2.09 |
| Pivot price | 1.69 |
|||
| Supports | First : | 1.53 | Second : | 1.28 |
| MAs | MA(5) : | 1.75  |
MA(20) : | 1.69 |
| MA(100) : | 1.47 |
MA(250) : | 1.72 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 33.9 |
D(3) : | 49.1 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 2.95 | Low : | 1.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ARAY ] has closed below upper band by 48.5%. Bollinger Bands are 3.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.76 - 1.77 | 1.77 - 1.78 |
| Low: | 1.65 - 1.66 | 1.66 - 1.67 |
| Close: | 1.68 - 1.7 | 1.7 - 1.72 |
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Fri, 10 Oct 2025
Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share Price - Sahm
Wed, 08 Oct 2025
First CyberKnife S7 SBRT Treatments: Accuray, 5D Clinics & Icon Group Begin Patient Care in Melbourne - Stock Titan
Wed, 08 Oct 2025
Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System - PR Newswire
Sat, 04 Oct 2025
Accuray (NASDAQ:ARAY) Shares Cross Above Two Hundred Day Moving Average - Time to Sell? - MarketBeat
Fri, 26 Sep 2025
Accuray Launches Stellar All-in-One Adaptive Radiotherapy System in US | ARAY Stock News - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 113 (M) |
| Shares Float | 109 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 71.5 (%) |
| Shares Short | 3,150 (K) |
| Shares Short P.Month | 2,220 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.72 |
| Profit Margin | -0.4 % |
| Operating Margin | 3.7 % |
| Return on Assets (ttm) | 1 % |
| Return on Equity (ttm) | -2.6 % |
| Qtrly Rev. Growth | 16.7 % |
| Gross Profit (p.s.) | 1.3 |
| Sales Per Share | 4.06 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -85.01 |
| PEG Ratio | 0 |
| Price to Book value | 2.36 |
| Price to Sales | 0.41 |
| Price to Cash Flow | 67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|